Edition:
United States

vTv Therapeutics Inc (VTVT.OQ)

VTVT.OQ on NASDAQ Stock Exchange Global Market

1.57USD
13 Jul 2018
Change (% chg)

$-0.01 (-0.63%)
Prev Close
$1.58
Open
$1.58
Day's High
$1.60
Day's Low
$1.53
Volume
11,021
Avg. Vol
235,169
52-wk High
$8.37
52-wk Low
$0.65

Select another date:

Tue, May 15 2018

BRIEF-vTv Therapeutics Q1 GAAP Loss Per Share $0.30

* VTV THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL AND OPERATIONAL RESULTS AND RECENT HIGHLIGHTS

BRIEF-VTV Therapeutics Announces Company Will Pre-Specify New Subgroup With The FDA

* VTV THERAPEUTICS ANNOUNCES COMPANY WILL PRE-SPECIFY NEW SUBGROUP WITH THE FDA AND REPORT PHASE 3 PART B RESULTS IN JUNE

BRIEF-Vtv Therapeutics Announces Topline Results From The First Steadfast Phase 3 Study Evaluating Azeliragon In People With Mild Alzheimer's Disease

* VTV THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE FIRST STEADFAST PHASE 3 STUDY EVALUATING AZELIRAGON IN PEOPLE WITH MILD ALZHEIMER’S DISEASE

BRIEF-vTv Therapeutics Says Phase 1B Study Of TTP399 For The Treatment Of Type 1 Diabetes Completed

* VTV THERAPEUTICS ANNOUNCES COMPLETION OF PHASE 1B STUDY EVALUATING TTP399 FOR THE TREATMENT OF TYPE 1 DIABETES Source text for Eikon: Further company coverage:

BRIEF-VTV Therapeutics Reports Q4 Loss Per Share $0.44

* VTV THERAPEUTICS REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL AND OPERATIONAL RESULTS AND RECENT HIGHLIGHTS

BRIEF-vTv Therapeutics Files For Stock Shelf Of Up To $250 Million

* VTV THERAPEUTICS INC FILES FOR STOCK SHELF OF UP TO $250 MILLION – SEC FILING‍​ Source text for Eikon: (http://bit.ly/2EUHrux) Further company coverage:

Select another date: